Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Postmenopausal Women (P06090)
Status:
Completed
Trial end date:
2005-02-15
Target enrollment:
Participant gender:
Summary
Both tibolone and raloxifene have been demonstrated to prevent postmenopausal bone loss.
During treatment with tibolone bone mineral density (BMD) of the spine has been shown to be
increased between 1.8 and 5.8 % above baseline in two years, depending on the population
studied. Since treatments aimed at prevention should ideally be used long-term, compliance
with the treatment is crucial. Efficacy of and compliance with the two treatments will be
measured and evaluated.